检索
AI 对话
AI 辅写
analysis
趋势分析
编组
数据平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Pembrolizumab plus vorinostat is highly active in Hodgkin lymphoma, including patients refractory to prior PD-1 blockade.

Matthew G Mei,Lu Chen,James Godfrey,Joo Y Song,Colt Egelston,Lihua Elizabeth Budde,Saro H Armenian,Liana Nikolaenko,Mary Nwangwu,Weihua Guo,Lei Gao,Peter Lee, Robert W Chen, Shari Daniels,Neena Kennedy,Lacolle Peters,Jasmine Zain,Steven T Rosen,Stephen J Forman,Leslie Popplewell, Larry W Kwak,Alex F Herrera

Blood（2023）

引用 0|浏览9
暂无评分
摘要
Pembrolizumab and vorinostat was well-tolerated with a high ORR rate in RR cHL including in anti-PD1-refractory disease.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要